REDUCTION IN HRQOL WITH INCREASING VOC FREQUENCY AMONG PATIENTS WITH SCD

Author(s)

Bailey M1, Bonner A2, Brown S2, Thompson M2
1Novartis Pharmaceuticals Corporation, Jersey City, NJ, USA, 2EVERSANA, Burlington, ON, Canada

OBJECTIVES: Sickle cell disease (SCD) is one of the most prevalent inherited diseases, with approximately 300,000 affected children born each year worldwide. A major cause of morbidity among patients with SCD is the occurrence of severely painful episodes, known as vaso-occlusive crisis (VOCs), which can impact quality of life and cause organ damage or even death. This study assessed the impact of VOC events on health-related quality of life (HRQoL) and associated utility of patients with SCD.

METHODS: The LEGACY registry (CICL670AUS38) is a prospective, multicenter, observational study that documented the outcomes of 498 SCD patients living in the United States. For the cohort of 181 adult patients (≥18 years), Short Form-36 (SF-36) Health Survey scores and VOCs were evaluated every 6 months for 3 years or until patient discontinuation. SF-36 scores were mapped to the EuroQoL five-dimension (EQ-5D) questionnaire. For each patient, the annualized rate of VOC events was calculated from first visit to each visit with HRQoL measures reported, and annualized VOC rates were subsequently grouped (<1, ≥1 to <3, ≥3 VOCs/year). Mean EQ-5D scores were compared between annualized VOC groups using generalized estimating equations to account for within-patient correlation across visits. Differences between the groups on the SF-36 component scores and SF-36 domains were also assessed.

RESULTS: Patients with ≥3 VOCs/year reported, on average, a mapped EQ-5D score 0.0697 lower (p = 0.014) than patients with <1 VOCs/year (0.6213 vs. 0.6910). Furthermore, patients who had ≥3 VOCs/year also showed, on average, a SF-36 Physical Component Score 2.480 lower (p = 0.025) compared to patients with <1 VOCs/year (48.684 vs. 51.164).

CONCLUSIONS: This analysis demonstrates the long-term impact of VOC frequency on HRQoL. SCD patients who had a higher number of annual VOCs were shown to have a worse HRQoL compared to patients with <1 VOCs/year.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Value in Health, Volume 23, Issue 5, S1 (May 2020)

Code

PRO91

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Rare and Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×